The latest guidelines strongly recommend the use of SGLT2 inhibitors and GLP1-RAs that include the more recent and increasing evidence on CV protection in high/very-high risk in the patients with T2DM; however, these are not yet so extensively applied by all the physicians. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.